A-to-I RNA Editing in Cancer: From Evaluating the Editing Level to Exploring the Editing Effects

As an important regulatory mechanism at the posttranscriptional level in metazoans, adenosine deaminase acting on RNA (ADAR)-induced A-to-I RNA editing modification of double-stranded RNA has been widely detected and reported. Editing may lead to non-synonymous amino acid mutations, RNA secondary st...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in oncology Vol. 10; p. 632187
Main Authors Wang, Heming, Chen, Sinuo, Wei, Jiayi, Song, Guangqi, Zhao, Yicheng
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 11.02.2021
Subjects
ADAR
cancer
circular RNAs
non-coding RNA
Oncology
RNA editing
RNA editing
ADAR
cancer
non-coding RNA
circular RNAs
Online AccessGet full text

Cover

More Information
Summary:As an important regulatory mechanism at the posttranscriptional level in metazoans, adenosine deaminase acting on RNA (ADAR)-induced A-to-I RNA editing modification of double-stranded RNA has been widely detected and reported. Editing may lead to non-synonymous amino acid mutations, RNA secondary structure alterations, pre-mRNA processing changes, and microRNA-mRNA redirection, thereby affecting multiple cellular processes and functions. In recent years, researchers have successfully developed several bioinformatics software tools and pipelines to identify RNA editing sites. However, there are still no widely accepted editing site standards due to the variety of parallel optimization and RNA high-seq protocols and programs. It is also challenging to identify RNA editing by normal protocols in tumor samples due to the high DNA mutation rate. Numerous RNA editing sites have been reported to be located in non-coding regions and can affect the biosynthesis of ncRNAs, including miRNAs and circular RNAs. Predicting the function of RNA editing sites located in non-coding regions and ncRNAs is significantly difficult. In this review, we aim to provide a better understanding of bioinformatics strategies for human cancer A-to-I RNA editing identification and briefly discuss recent advances in related areas, such as the oncogenic and tumor suppressive effects of RNA editing.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
These authors have contributed equally to this work
This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Oncology
Edited by: Yue Hou, Northeastern University, China
Reviewed by: Jun-Hao Li, University of California, San Diego, United States; Giovanni Nigita, The Ohio State University, United States
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2020.632187